The Future of Genetic Therapeutics

Discovering life-changing scientific and medical advancements

MISSION

We are changing the way the scientific and medical communities approach white matter disorders

Myrtelle is a gene therapy company whose mission is to transform the treatment of neurological diseases.

Through our core technologies, assets, patents and expertise, we have built a platform to address an array of diseases with white matter involvement.

Discover Our Technology
OUR VISION

Our vision rests in our ongoing dedication to changing the treatment, abilities, and quality of life of those afflicted by devastating neurological disorders for whom few, if any, treatment options exist.

Learn More
CLINICAL TRIAL

Learn more about our innovative clinical work for the treatment of the rare monogenetic disorder, Canavan disease

Find a Trial
TECHNOLOGY

Our commitment to our proprietary technologies enables innovative approaches to hundreds of disorders involving myelin.

Explore Solutions
STRATEGIC PARTNERSHIPS

Collaborations that Lead to Change

We cultivate strategic partnerships which allow us to further our mission through alliances in scientific research, development, manufacturing, and more, including an exclusive IP license with Pfizer Inc.

Learn More
LEARN MORE

Understanding Gene Therapy for Rare CNS Diseases

Download